Neurofibromatosis Type 1-Related Hydrocephalus: Treatment Options and Considerations.


Journal

World neurosurgery
ISSN: 1878-8769
Titre abrégé: World Neurosurg
Pays: United States
ID NLM: 101528275

Informations de publication

Date de publication:
Aug 2019
Historique:
received: 27 01 2019
revised: 26 04 2019
accepted: 27 04 2019
pubmed: 7 5 2019
medline: 22 1 2020
entrez: 7 5 2019
Statut: ppublish

Résumé

Neurofibromatosis type I (NF1) will be associated with hydrocephalus in ≤13% of cases. Currently, very little data are available describing the actual etiologies and treatment options of NF1-associated hydrocephalus. We, therefore, have described our experience in treating NF1-associated hydrocephalus. We completed a retrospective data analysis of 1020 patients with NF1 treated at the Gilbert's Israeli International Neurofibromatosis Center during a period of 20 years. The patients presenting with, and treated for, related hydrocephalus were included. The clinical, radiological, and surgical data are presented. We included 22 patients (2.1% of the entire NF1 patient cohort), with 17 aged <19 years. Twenty patients had obstructive hydrocephalus. The most common etiologies included aqueductal or third ventricular obstruction. Of the 22 patients, 15 had underwent endoscopic procedures (14 third ventriculostomies) and 7 had undergone shunt procedures. The corresponding failure rates (including the need for additional cerebrospinal fluid procedures) were 60% and 71%. Hydrocephalus in the context of NF1 has been caused mostly by obstructive etiologies. A tailored treatment approach is recommended to address the specific etiology. Regardless of the treatment approach, a relatively high rate of failure has been described.

Identifiants

pubmed: 31059857
pii: S1878-8750(19)31228-8
doi: 10.1016/j.wneu.2019.04.231
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e664-e668

Informations de copyright

Copyright © 2019 Elsevier Inc. All rights reserved.

Auteurs

Jonathan Roth (J)

Department of Pediatric Neurosurgery, Dana Children's Hospital, Tel-Aviv Medical Center, Tel-Aviv, Israel; The Gilbert Israeli International Neurofibromatosis Center, Tel-Aviv Medical Center, Tel-Aviv, Israel. Electronic address: jonaroth@gmail.com.

Roee Ber (R)

Department of Pediatric Neurosurgery, Dana Children's Hospital, Tel-Aviv Medical Center, Tel-Aviv, Israel.

Shlomi Constantini (S)

Department of Pediatric Neurosurgery, Dana Children's Hospital, Tel-Aviv Medical Center, Tel-Aviv, Israel; The Gilbert Israeli International Neurofibromatosis Center, Tel-Aviv Medical Center, Tel-Aviv, Israel.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH